<?xml version="1.0"?>
<feed xmlns="http://www.w3.org/2005/Atom" xml:lang="ro">
	<id>https://wiki.tradeville.ro/index.php?action=history&amp;feed=atom&amp;title=PHIO_PHARMACEUTICALS_CORPORATION_%28consolidare%29</id>
	<title>PHIO PHARMACEUTICALS CORPORATION (consolidare) - Revizia istoricului</title>
	<link rel="self" type="application/atom+xml" href="https://wiki.tradeville.ro/index.php?action=history&amp;feed=atom&amp;title=PHIO_PHARMACEUTICALS_CORPORATION_%28consolidare%29"/>
	<link rel="alternate" type="text/html" href="https://wiki.tradeville.ro/index.php?title=PHIO_PHARMACEUTICALS_CORPORATION_(consolidare)&amp;action=history"/>
	<updated>2026-05-09T21:43:11Z</updated>
	<subtitle>Istoricul versiunilor pentru această pagină din wiki</subtitle>
	<generator>MediaWiki 1.39.2</generator>
	<entry>
		<id>https://wiki.tradeville.ro/index.php?title=PHIO_PHARMACEUTICALS_CORPORATION_(consolidare)&amp;diff=435737&amp;oldid=prev</id>
		<title>Admin: Pagină nouă: Pagina dedicata companiei PHIO PHARMACEUTICALS CORPORATION (consolidare) listata cu simbolul US.PHIO  ==Descriere companie== Phio Pharmaceuticals Corp. (https://phiopharma.com/) is a biotechnology company. The Company is focused on developing immuno-oncology therapeutics based on its self-delivering ribonucleic acid interface (RNAi) INTASYL therapeutic platform. The Company has developed a product platform based on its INTASYL technology that allows selective non-genetically...</title>
		<link rel="alternate" type="text/html" href="https://wiki.tradeville.ro/index.php?title=PHIO_PHARMACEUTICALS_CORPORATION_(consolidare)&amp;diff=435737&amp;oldid=prev"/>
		<updated>2024-09-18T18:21:21Z</updated>

		<summary type="html">&lt;p&gt;Pagină nouă: Pagina dedicata companiei PHIO PHARMACEUTICALS CORPORATION (consolidare) listata cu simbolul US.PHIO  ==Descriere companie== Phio Pharmaceuticals Corp. (https://phiopharma.com/) is a biotechnology company. The Company is focused on developing immuno-oncology therapeutics based on its self-delivering ribonucleic acid interface (RNAi) INTASYL therapeutic platform. The Company has developed a product platform based on its INTASYL technology that allows selective non-genetically...&lt;/p&gt;
&lt;p&gt;&lt;b&gt;Pagină nouă&lt;/b&gt;&lt;/p&gt;&lt;div&gt;Pagina dedicata companiei PHIO PHARMACEUTICALS CORPORATION (consolidare) listata cu simbolul US.PHIO&lt;br /&gt;
&lt;br /&gt;
==Descriere companie==&lt;br /&gt;
Phio Pharmaceuticals Corp. (https://phiopharma.com/) is a biotechnology company. The Company is focused on developing immuno-oncology therapeutics based on its self-delivering ribonucleic acid interface (RNAi) INTASYL therapeutic platform. The Company has developed a product platform based on its INTASYL technology that allows selective non-genetically modified programming of adoptive cell therapy (ACT) cells and of the tumor micro-environment (TME), resulting in reduced immune inhibition and in improved immunotherapy. Its lead product candidate, PH-762, is an INTASYL compound that targets the checkpoint protein PD-1, which acts as a type of switch that prevents T cells from attacking certain cells, such as cancer cells, in the body. Its second product candidate, PH-894, is an INTASYL compound that targets BRD4, which is a regulator of gene expression impacting cell differentiation. It is also developing PH-804, which targets the suppressive immune receptor TIGIT.&lt;br /&gt;
&lt;br /&gt;
==Grafic actiuni companie==&lt;br /&gt;
&amp;lt;iframe key=&amp;quot;tradeville&amp;quot; path=&amp;quot;graficSimbol/US.PHIO&amp;quot; /&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Ultimele stiri despre PHIO PHARMACEUTICALS CORPORATION (consolidare) (US.PHIO)==&lt;br /&gt;
&amp;lt;dynamicpagelist&amp;gt;&lt;br /&gt;
category=US.PHIO&lt;br /&gt;
count=10&lt;br /&gt;
order=descending&lt;br /&gt;
addfirstcategorydate=false&lt;br /&gt;
&amp;lt;/dynamicpagelist&amp;gt;&lt;br /&gt;
&lt;br /&gt;
[[Categorie:US.PHIO]][[Categorie:Stiri despre companii]]&lt;/div&gt;</summary>
		<author><name>Admin</name></author>
	</entry>
</feed>